Antioxidant and Organ Protective Potential of the
Consciousness Energy Healing-Based Novel Test
Formulation Using Different Biomarkers Analysis
Volume 3 - Issue 4
Kathryn Regina Sweas1, Mahendra Kumar Trivedi1, Alice Branton1, Dahryn Trivedi1, Gopal Nayak1, Sambhu Charan
Mondal2 and Snehasis Jana2*
-
Author Information
Open or Close
- 1Trivedi Global, Inc., Henderson, Nevada, USA
- 2Trivedi Science Research Laboratory Pvt. Ltd., Thane-West, Maharashtra, India
*Corresponding author:
Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Thane-West, Maharashtra, India
Received:June 17, 2019; Published:June 27, 2019;
DOI: 10.32474/RRHOAJ.2019.03.000166
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
The aim of this paper was to investigate the impact of the Biofield Energy Treatment on the test formulation by focusing on
the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell
media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a
renowned Biofield Energy Healer, Kathryn Regina Sweas, USA and was labeled as the Biofield Energy Treated (BT) test formulation/
media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental
group of Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5%, 127.9%, and 53.3%
restoration of cell viability, at 0.1, 10, and 25 μg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UTMed
+ UT-TI group. Moreover, UT-Med + BT-TI and BT-Med + BT-TI groups showed 42.4% (at 25 μg/mL) and 72.6% (at 0.1 μg/mL),
restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 67.7% restoration
of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1 μg/
mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 80.7%, 85%, and 93.7% in the
UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 μg/mL in human bone osteosarcoma cells (MG-63)
compared to the untreated. Additionally, the level of ALP was significantly increased by 65.8% (at 25 μg/mL) and 106.7% (at 50
μg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa)
compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased
by 100.9% (at 0.1 μg/mL) and 91.2% (at 10 μg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to
the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by
51.5% and 133.6% at 10 and 63 μg/mL, respectively in the BT-Med + BT-TI group compared to untreated in HepG2 cells. The percent
protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 55.8% (at 10 μg/mL) and 43.8% (at 1 μg/
mL) in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated in A549 cells. Serotonin level was
significantly increased by 80%, 77.2%, and 58.7% in the BT-Med + BT-TI group at 10, 25, and 63 μg/mL, respectively as compared to
untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly
increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50
μg/mL compared to the untreated in MG-63 cells. Altogether, results suggest that Biofield Treated test formulation significantly
improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers also to protect and maintain the normal function of
each vital organs. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders
such as coronary artery disease, heart attack, congenital heart disease, heart failure, arrhythmias, cirrhosis, cardiomyopathy, liver
cancer, Wilson disease, hemochromatosis, pneumonia, chronic bronchitis, asthma, cystic fibrosis, emphysema, osteoporosis, etc.
Keywords: The Trivedi Effect®; Consciousness Energy Treatment, Bone health; Liver health; Cardiac health; Lungs health; Brain
health; VDR receptor
Abstract|
Introduction|
Materials and Methods|
Results and Discussions|
Conclusion|
Acknowledgement|
References|